Working… Menu

Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01562626
Recruitment Status : Recruiting
First Posted : March 26, 2012
Last Update Posted : July 5, 2019
Information provided by (Responsible Party):
Anaeropharma Science, Inc.

Tracking Information
First Submitted Date  ICMJE March 22, 2012
First Posted Date  ICMJE March 26, 2012
Last Update Posted Date July 5, 2019
Study Start Date  ICMJE September 2012
Estimated Primary Completion Date February 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 22, 2012)
Number of participants with adverse events as a measure of safety and tolerability of APS001F treatment plus 5-FC and maltose [ Time Frame: Starting from date of first dose up to 30 days after last dose ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Official Title  ICMJE A Phase I/II Safety, Pharmacokinetic, and Pharmacodynamic Study of APS001F With Flucytosine and Maltose for the Treatment of Advanced and/or Metastatic Solid Tumors
Brief Summary The purpose of this study is to test the safety and efficacy of an investigational drug called APS001F when given with flucytosine (5-FC) for treatment of solid tumors. APS001F is a recombinant Bifidobacterium longum (a live bacteria normally found in the digestive tract) that has been modified to produce an enzyme, cytosine deaminase (CD). The patient will first receive an injection of APS001F followed by oral 5-FC. APS001F is expected to go to the site of the tumor(s) where the agent will produce CD enzyme. CD enzyme will convert the 5-FC into 5-fluorouracil (5-FU) which is a standard chemotherapy drug for several types of cancer. Additionally, some patients will also receive 10% maltose injection, a sugar that has been shown to enhance the growth and effectiveness of APS001F in animals. This is the first study where APS001F is being used in humans.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Tumors
  • Neoplasms
  • Cancer
Intervention  ICMJE
  • Drug: APS001F
    APS001F infusion on Days 1,2,3 of each 28 day cycle.
  • Drug: Flucytosine (5-FC)
    oral doses on Days 11-15 and 18-22, each 28 day cycle
  • Drug: 10% maltose
    10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
Study Arms  ICMJE Experimental: Dose escalation
  • Drug: APS001F
  • Drug: Flucytosine (5-FC)
  • Drug: 10% maltose
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 22, 2012)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE February 2021
Estimated Primary Completion Date February 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients with advanced and/or metastatic, histologically documented solid tumors.
  2. Patients must have disease that is no longer considered responsive to available conventional modalities or treatments (failed any known standard curative or effective therapy for that disease).
  3. Patients must have measurable or evaluable advanced and/or metastatic disease by RECIST 1.1.
  4. Patients enrolled at Dose Level 6 or higher in the phase I portion of the trial must have at least one tumor mass suitable and easily accessible for excisional biopsy, or alternatively, accessible for CT or ultrasound guided core needle biopsy. The procedure must be able to be performed with minimum morbidity.
  5. ECOG Performance status of 0 or 1.
  6. Must be at least 18 years of age.
  7. Expected survival of at least 3 months.
  8. Men and women of child-bearing potential (i.e., women who are premenopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device (IUD), oral contraceptive or double barrier device), and women must have a negative serum or urine pregnancy test 1 week before beginning treatment on this trial. Nursing patients are also excluded.
  9. Must be able and willing to give written informed consent.
  10. Patients must have adequate major organ function and meet the following criteria:

    • white blood cell (WBC)count >= 3,000/mm3.
    • Absolute neutrophil count (ANC) >= 1500/uL.
    • Platelets >= 100,000/mm3.
    • Hemoglobin >= 9.0g/dL
    • Serum creatinine <= 1.5 mg/dL. (or estimated creatinine clearance >= 50 ml/min/1.73 m2)
    • Bilirubin <= 1.5 mg/dL; ALT, AST, and alkaline phosphatase <= 3.0x the upper limit of normal
    • Prothrombin Time (PT) and activated partial thromboplastin time (aPTT) <= 1.5x the upper limit of normal.
    • Oxygen saturation >= 90% by pulse oximetry
  11. Patients should have body Temperature <= 38.0 degrees C.
  12. Echocardiogram demonstrated left ventricular ejection fraction >= 40%.

Exclusion Criteria:

  1. Presence or history of brain metastases.
  2. Presence of known or suspected ongoing ischemia of non-tumor tissues including

    • ischemic peripheral vascular disease, myocardial infarction within the past 6 months,
    • congestive heart failure > class II NYHA,
    • unstable angina (anginal symptoms at rest) or new onset angina (i.e., began within the last 3 months).
    • cerebrovascular accident, including transient ischemic attacks within the past 6 months.
  3. An artificial implant that cannot be easily removed (e.g., heart valves, prosthetic hips or knees, or other devices), which could allow a nidus of infection.
  4. Patients with indwelling catheters (other than Portacath, Hickman or PICC lines)
  5. Known cardiac valvular disease (e.g. bicuspid aortic valve) or arterial aneurysm(s) that may allow a nidus of infection.
  6. Known cardiac arrhythmias requiring medication.
  7. Patients with any of the following cardiovascular conditions: patent foramen ovale, prior history of bacterial endocarditis, any existing thrombus (either arterial or venous) as well as known history of DVT, permanent pacemakers, AICDs, LVADs, or other intravascular cardiac device, known AV malformations.
  8. Patients with baseline respiratory insufficiency severe enough to require supplemental oxygen.
  9. Patients with pleural effusion or abdominal/peritoneal ascites, except the finding of physiological levels of fluid.
  10. Patients who have not fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment). The required minimum time elapsed from prior treatments are:

    • treatment with cytotoxic agents, or treatment with biologic agents within 4 weeks prior to treatment with APS001F (6 weeks for mitomycin C or nitrosoureas).
    • treatment with molecular targeted agents within 2 weeks prior to treatment with APS001F.
    • radiotherapy within 4 weeks prior to treatment with APS001F (intensive radiotherapy within 6 weeks or palliative radiotherapy within 2 weeks).
    • At least 2 weeks must have elapsed from any prior surgery or hormonal therapy.
  11. Presence of GI bleeding.
  12. Currently using warfarin.
  13. Active infection of any kind.
  14. Currently using antibiotics and/or anti fungal agent (however, topical antibiotics are permitted).
  15. Presence of any condition or concurrent requirement for treatment with agents known to result in immune deficiency.
  16. Patients with documented immunodeficiency such as HIV infection.
  17. Presence of autoimmune disease that requires corticosteroids and/or immunosuppressive agents.
  18. Patients with evidence of chronic active Hepatitis B (positive for HbsAg) and Hepatitis C (positive for viral RNA).
  19. Hypersensitivity (history of allergic reactions) to

    • 5-FC
    • 5-FU
  20. Patient's medical history does not contraindicate treatment with at least one of the following antibiotics: ampicillin, clindamycin and erythromycin/clarithromycin.
  21. Unwilling or unable to follow protocol requirements.
  22. Presence of any concurrent illness or condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT01562626
Other Study ID Numbers  ICMJE APS001F-001
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Anaeropharma Science, Inc.
Study Sponsor  ICMJE Anaeropharma Science, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Anaeropharma Science, Inc.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP